Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | DRD3 | P35462 | 5/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 6/20 | 0.42 |
| ▸ | HRH2 | P25021 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080345 | 0.96 | AR (0.60) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3074762 | 0.89 | AR (0.72) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3711734 | 0.87 | AR (0.56) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3061952 | 0.87 | AR (0.73) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3077069 | 0.85 | AR (0.53) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3071463 | 0.85 | AR (0.78) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3075158 | 0.85 | AR (0.61) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3081238 | 0.83 | AR (0.60) | ARKCNH2HTR1ADRD2HTR2A | |
| SCHEMBL3069850 | 0.82 | AR (0.79) | ARKCNH2DRD2HTR2ADRD3 | |
| SCHEMBL3056879 | 0.81 | AR (0.58) | ARKCNH2HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | claimed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | claimed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885KCNH2 2070/4885HTR1A 1155/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885KCNH2 1878/4885HTR1A 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.